Osteoporosis

Abaloparatide can prevent bone fractures in postmenopausal women with osteoporosis.

Development of odanacatib has been discontinued, and regulatory approval will not be sought.

Approximately 14% of women who took calcium supplements developed dementia.

CBCT/CMOS can image trabecular bone more easily than the current method.

Approximately 1 in 2 women and up to 1 in 4 men 50 years and older will break a bone due to osteoporosis.

The drug binds to sclerostin and increases bone formation for osteoporosis in postmenopausal women.

The Bone Balance Index can strongly predict patients at risk for bone loss after menopause.

RANK-inhibitor denosumab was able to stop cell growth and reduce cancer development in breast cancer samples with mutated-BRCA1.

Top news of the day from across the healthcare landscape.

Little clinical guidance exists on how soon after a fracture occurs that osteoporosis medications should be prescribed.

Abaloparatide-SC found to boost bone mineral density in osteoporosis.

Evista is typically given to women after menopause to treat and prevent osteoporosis and reduce the risk of invasive breast cancer.

The FDA has approved Glenmark Pharmaceuticals Inc's abbreviated new drug application for raloxifene hydrochloride tablets USP, 60 mg, which is the therapeutic equivalent to Eli Lilly and Company's Evista.

Totaling more than 2 million, women comprise the fastest-growing group within the veteran population.

Less is more for women receiving osteoporosis drug therapy, as new research suggests that this patient population may be overtreated.

Too much calcium can't be good, right?

Teva recently launched risedronate sodium tablets, the generic version of Actavis's Actonel bisphosphonate, in 3 dosage strengths.

Women with the greatest risk for osteoporosis are not being screened enough, while those at less risk are being screened too often.

Gastroprotective agents may be needed in postmenopausal women taking bisphosphonates.

Controlling seizures is critical for patients with epilepsy, but side effects of antiepileptic drugs are another tremendous concern.

The high cost of bisphosphonates may outweigh the drugs' benefit in reducing hip fracture rates.

A postmenopausal woman's score on a fracture risk scale can tip off her clinicians to gum disease.

Supplementation with alkaline potassium salts aids bone health and reduces osteoporosis risk.

Many male patients being treated for prostate cancer undergo androgen deprivation therapy, which has been shown to have several risky side effects, including osteoporosis.

Women who take bisphosphonates, which are commonly used to treat osteoporosis and other bone conditions, have about half the risk of developing endometrial cancer as women who do not use the drugs. This study supports other research showing that bisphosphonates may have an anticancer effect.

The media has been quick to discuss research findings on vitamin D supplementation's potential role in combating osteoporosis, correcting deficiency in chronic kidney disease, improving heart health, and extending life, which raises the question of whether patients should be screened routinely for vitamin D deficiency.

Well-trained pharmacy technicians can free up pharmacists' time for osteoporosis management services by identifying patients who do not require pharmacist intervention.

Drugs commonly used to treat osteoporosis may benefit patients with diseases like breast cancer.

Current risk assessment strategies for reducing fractures related to osteoporosis among women fail to accurately predict who will experience major osteoporotic injuries.

Pharmacist-led drug use evaluation programs improve osteoporosis management in general practice.